Literature DB >> 1401194

Evaluation of modified passive haemagglutination assay for Vi antibody estimation in Salmonella typhi infections.

G Kang1, G Sridharan, M V Jesudason, T J John.   

Abstract

A simple passive haemmagglutination assay (PHA) was developed to detect Vi antibodies, to improve the diagnosis of typhoid fever by small laboratories. The Vi capsular antigen of Salmonella typhi was extracted by alternate alcohol and acetone precipitation. Formalin fixed, sheep red blood cells treated with chromium chloride were sensitised with this Vi antigen and antibodies detected and measured by PHA. The test had a sensitivity of 83.3% among 30 cases of typhoid fever confirmed by culture. The specificity of the test was 94%, making it suitable for use in laboratories without facilities for IFAT or ELISA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1401194      PMCID: PMC495163          DOI: 10.1136/jcp.45.8.740

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  5 in total

1.  Preparation of formalinized erythrocytes.

Authors:  L CSIZMAS
Journal:  Proc Soc Exp Biol Med       Date:  1960-01

2.  Isolation of Vi antigen and a simple method for its measurement.

Authors:  K H Wong; J C Feeley
Journal:  Appl Microbiol       Date:  1972-10

3.  Comparison of the Vi indirect fluorescent antibody test with the Widal agglutination method in the serodiagnosis of typhoid fever.

Authors:  N Doshi; A G Taylor
Journal:  J Clin Pathol       Date:  1984-07       Impact factor: 3.411

4.  Enzyme-linked immunosorbent assay for detection of human antibodies to Salmonella typhi Vi antigen.

Authors:  T J Barrett; P A Blake; S L Brown; K Hoffman; J M Llort; J C Feeley
Journal:  J Clin Microbiol       Date:  1983-04       Impact factor: 5.948

5.  Vi serology in detection of chronic Salmonella typhi carriers in an endemic area.

Authors:  C F Lanata; M M Levine; C Ristori; R E Black; L Jimenez; M Salcedo; J Garcia; V Sotomayor
Journal:  Lancet       Date:  1983-08-20       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.